Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nexafed Gains Rite Aid Sales, But Stumbles In Extraction-Proof PSE Tests

This article was originally published in The Tan Sheet

Executive Summary

As Nexafed distribution picks up momentum, Acura hits a setback in developing a 100% extraction-resistant formulation of its PSE decongestant. Rite Aid, the first national drug store chain to carry Nexafed, is selling only tamper-deterrent, single-ingredient PSE formulations in West Virginia and will consider making the change in other states.

You may also be interested in...



PSE Product Makes “Highly” Tamper-Resistant Claim With 100% Out Of Reach

Westport Pharmaceuticals says a claim of being “highly” resistant to PSE-extraction distinguishes Zephrex-D from the competition, but the distinction alone is not adding up to market-share gains in the nonprescription nasal decongestant space.

PSE Product Makes “Highly” Tamper-Resistant Claim With 100% Out Of Reach

Westport Pharmaceuticals says a claim of being “highly” resistant to PSE-extraction distinguishes Zephrex-D from the competition, but the distinction alone is not adding up to market-share gains in the nonprescription nasal decongestant space.

Tamper-Resistant Pseudoephedrine Sparks Pharmacies’ Interest

Ohio and West Virginia chain Fruth Pharmacy begins replacing the 30 mg PSE products available in its stores with Acura Pharmaceuticals’ Nexafed product. Meanwhile, DEA says Westport Pharmaceuticals should not make an extraction-proof claim for its Zephrex-D PSE product.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel